Skip to main content

Table 1 Demographic and baseline characteristics of the patients

From: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Characteristic Secukinumab IV-300 mg (N = 76) Secukinumab IV-150 mg (N = 74) Placebo (N = 76)
Age (years), mean (SD) 42.1 (11.8) 42.9 (11.1) 42.7 (11.4)
Male, n (%) 50 (65.8) 46 (62.2) 40 (52.6)
White, n (%) 52 (68.4) 54 (73.0) 58 (76.3)
Weight (kg), mean (SD) 82.7 (16.9) 80.3 (19.2) 79.0 (15.5)
Time since AS diagnosis (years), mean (SD) 5.3 (7.3) 6.0 (7.2) 5.2 (6.4)
HLA-B27-positive at baseline, n (%) 56 (73.7) 52 (70.3) 53 (69.7)
Anti-TNF-naïve, n (%) 57 (75.0) 57 (77.0) 59 (77.6)
Total BASDAI score, mean (SD) 7.0 (1.4) 7.0 (1.4) 6.9 (1.3)
hsCRP (mg/L), median (min–max) 13.3 (0.2–65.1) 21.1 (0.4–111.3) 20.0 (0.2–112.5)
Total back pain score (0–100 mm scale), mean (SD) 74.1 (15.1) 75.2 (14.9) 75 (13.9)
Baseline systemic treatment, n (%)
 Methotrexate use at randomization 13 (17.1) 10 (13.5) 6 (7.9)
 Sulfasalazine use at randomization 20 (26.3) 14 (18.9) 19 (25.0)
 Corticosteroid use at randomization 6 (7.9) 9 (12.2) 14 (18.4)
 NSAID use at randomization 63 (82.9) 62 (83.8) 64 (84.2)
  1. n number of patients, SD standard deviation, AS ankylosing spondylitis, HLA human leukocyte antigen, TNF tumor necrosis factor, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, NSAID non-steroidal anti-inflammatory drugs